tetano
Editor, Senior Moderator
Cancer Med
. 2023 Apr 26.
doi: 10.1002/cam4.5996. Online ahead of print. Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
Tomotaka Suzuki[SUP] 1 [/SUP], Shigeru Kusumoto[SUP] 1 [/SUP], Yoshiko Kamezaki[SUP] 2 [/SUP], Hiroya Hashimoto[SUP] 3 [/SUP], Nozomi Nishitarumizu[SUP] 1 [/SUP], Yoko Nakanishi[SUP] 1 [/SUP], Yukiyasu Kato[SUP] 1 [/SUP], Akimi Kawai[SUP] 1 [/SUP], Naohiro Matsunaga[SUP] 1 [/SUP], Toru Ebina[SUP] 1 [/SUP], Tomoyuki Nakamura[SUP] 1 [/SUP], Yoshiaki Marumo[SUP] 1 [/SUP], Kana Oiwa[SUP] 1 [/SUP], Shiori Kinoshita[SUP] 1 [/SUP], Tomoko Narita[SUP] 1 [/SUP], Asahi Ito[SUP] 1 [/SUP], Atsushi Inagaki[SUP] 1 [/SUP], Masaki Ri[SUP] 1 [/SUP], Hirokazu Komatsu[SUP] 1 [/SUP], Takashi Aritsu[SUP] 2 [/SUP], Shinsuke Iida[SUP] 1 [/SUP]
Affiliations
Background: The recently developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions, such as plasma cell dyscrasia (PCD).
Methods: We retrospectively measured serum SARS-CoV-2 antibodies against the spike protein (S-IgG) after the second and third mRNA vaccine doses (doses 2 and 3, respectively) in 109 patients with PCD. We evaluated the proportion of patients with an adequate humoral response (defined as S-IgG titers ≥300 antibody units/mL).
Results: Although active anti-myeloma treatments prior to vaccination had a significantly negative impact on adequate humoral response, specific drug subclasses including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies were not negatively associated, except for B-cell maturation antigen-targeted therapy. Dose 3 (booster vaccination) led to significantly higher S-IgG titers and more patients acquired an adequate humoral response. Furthermore, evaluation of vaccine-induced cellular immune response in patients using T-spot Discovery SARS-CoV-2 kit, revealed an enhanced cellular immune response after Dose 3.
Conclusions: This study highlighted the significance of booster SARS-CoV-2 mRNA vaccination in patients with PCD with respect to humoral and cellular immunity. Moreover, this study highlighted the potential impact of certain drug subclasses on vaccine-induced humoral immune response.
Keywords: SARS-CoV-2; humoral and cellular immune response; mRNA vaccination; multiple myeloma; plasma cell dyscrasia.
. 2023 Apr 26.
doi: 10.1002/cam4.5996. Online ahead of print. Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
Tomotaka Suzuki[SUP] 1 [/SUP], Shigeru Kusumoto[SUP] 1 [/SUP], Yoshiko Kamezaki[SUP] 2 [/SUP], Hiroya Hashimoto[SUP] 3 [/SUP], Nozomi Nishitarumizu[SUP] 1 [/SUP], Yoko Nakanishi[SUP] 1 [/SUP], Yukiyasu Kato[SUP] 1 [/SUP], Akimi Kawai[SUP] 1 [/SUP], Naohiro Matsunaga[SUP] 1 [/SUP], Toru Ebina[SUP] 1 [/SUP], Tomoyuki Nakamura[SUP] 1 [/SUP], Yoshiaki Marumo[SUP] 1 [/SUP], Kana Oiwa[SUP] 1 [/SUP], Shiori Kinoshita[SUP] 1 [/SUP], Tomoko Narita[SUP] 1 [/SUP], Asahi Ito[SUP] 1 [/SUP], Atsushi Inagaki[SUP] 1 [/SUP], Masaki Ri[SUP] 1 [/SUP], Hirokazu Komatsu[SUP] 1 [/SUP], Takashi Aritsu[SUP] 2 [/SUP], Shinsuke Iida[SUP] 1 [/SUP]
Affiliations
- PMID: 37102222
- DOI: 10.1002/cam4.5996
Background: The recently developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions, such as plasma cell dyscrasia (PCD).
Methods: We retrospectively measured serum SARS-CoV-2 antibodies against the spike protein (S-IgG) after the second and third mRNA vaccine doses (doses 2 and 3, respectively) in 109 patients with PCD. We evaluated the proportion of patients with an adequate humoral response (defined as S-IgG titers ≥300 antibody units/mL).
Results: Although active anti-myeloma treatments prior to vaccination had a significantly negative impact on adequate humoral response, specific drug subclasses including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies were not negatively associated, except for B-cell maturation antigen-targeted therapy. Dose 3 (booster vaccination) led to significantly higher S-IgG titers and more patients acquired an adequate humoral response. Furthermore, evaluation of vaccine-induced cellular immune response in patients using T-spot Discovery SARS-CoV-2 kit, revealed an enhanced cellular immune response after Dose 3.
Conclusions: This study highlighted the significance of booster SARS-CoV-2 mRNA vaccination in patients with PCD with respect to humoral and cellular immunity. Moreover, this study highlighted the potential impact of certain drug subclasses on vaccine-induced humoral immune response.
Keywords: SARS-CoV-2; humoral and cellular immune response; mRNA vaccination; multiple myeloma; plasma cell dyscrasia.